Pfizer ends clinical Trials of DMD drug domagrozumab after disappointing results
Pfizer, the US pharmaceutical giant, has announced the discontinuation of two ongoing clinical trials for its drug domagrozumab (PF-06252616), intended to treat Duchenne muscular dystrophy (DMD). This decision comes after the trials failed to meet primary efficacy endpoints. The trials, identified as B5161002 and B5161004, were designed to evaluate the safety and efficacy of domagrozumab, […]